NCT03926624: An ongoing trial by Delta-Fly Pharma, Inc.
This trial is ongoing. It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03926624 |
|---|---|
| Title | Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 22, 2019 |
| Completion date | Dec. 31, 2025 |
| Required reporting date | Dec. 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 4, 2025 |
| Days late | None |